"As we wrap up our CTA-enabling studies, OMS721 continues to impress with its potential competitive advantages, including subcutaneous administration, convenient dosing, and maintenance of the acquired immune response to infection," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "OMS721 holds significant promise to treat a wide range of immune-related disorders, and today's data further underscore the commercial opportunities for OMS721. We plan to focus initially on aHUS, a rare and life-threatening indication seen most commonly in children. Submission of our CTA is expected next quarter, and we look forward to evaluating the drug product soon in clinical trials."About Omeros' MASP-2 Program
Omeros Announces Toxicology Data That Support Advancing MASP-2 Inhibitor Into Clinical Trials
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.